Mark Oberdoerster, MD
Internal Medicine · Ann Arbor, MINPI 1932197423
Payments from drug & device makers
Across 86 payments — averaging $17.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$331
- Novo Nordisk$181
- Pfizer$139
- Sanofi$125
- Amgen$123
- Novartis$119
- plus $448 from 13 others
What the payments were for
- Food & beverage$1,459100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 13 | $331 |
| Novo Nordisk | 16 | $181 |
| Pfizer | 10 | $139 |
| Sanofi | 1 | $125 |
| Amgen(2 entities) | 7 | $123 |
| Novartis | 8 | $119 |
| Merck | 5 | $67 |
| Boehringer Ingelheim | 4 | $56 |
| Sanofi-aventis U.S. LLC | 4 | $53 |
| Lilly USA, LLC | 4 | $50 |
| AstraZeneca | 3 | $45 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| GSK | 1 | $30 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Sanofi Pasteur Inc. | 2 | $27 |
| Astellas Pharma US Inc | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $13 |
| Circassia Inc. | 1 | $12 |
| Mannkind Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$125
How this compares
$1,465 in reported general payments places this provider in the 75th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 307 | $418,870 |
| EliquisApixaban | 252 | $333,505 |
| TrulicityDulaglutide | 53 | $88,496 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $80,815 |
| XareltoRivaroxaban | 52 | $80,582 |
| OzempicSemaglutide | 48 | $61,905 |
| MounjaroTirzepatide | 54 | $54,936 |
| RybelsusSemaglutide | 28 | $53,419 |
| FarxigaDapagliflozin Propanediol | 33 | $49,970 |
| JanuviaSitagliptin Phosphate | 32 | $47,103 |
| Atorvastatin Calcium | 1,179 | $18,512 |
| InvokanaCanagliflozin | 11 | $17,927 |
| Repatha SureclickEvolocumab | 17 | $14,790 |
| Repatha SyringeEvolocumab | 14 | $13,925 |
| Humalog Kwikpen U-100Insulin Lispro | 26 | $13,035 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $56 | $418,870307 claims |
| PfizerEliquis | $139 | $333,505252 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $50 | $143,432107 claims |
| Novo NordiskOzempic, Rybelsus | $181 | $115,32476 claims |
| Johnson & JohnsonXarelto, Invokana | $331 | $98,50963 claims |
| GSKTrelegy Ellipta | $30 | $80,81556 claims |
| MerckJanuvia, Dulera | $67 | $53,47743 claims |
| AstraZenecaFarxiga | $45 | $49,97033 claims |
| Astellas Pharma US IncMyrbetriq | $23 | $10,14714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Ann Arbor
- Ulka VaishampayanAnn Arbor$33.7M
- Terry SmithAnn Arbor$2.3M
- Gazala KhanAnn Arbor$2M
- Vikas SinghAnn Arbor$737K
- A FendrickAnn Arbor$347K
- Todd KoellingAnn Arbor$214K
- Ryann SohaneyAnn Arbor$167K
- Jeffrey PottsBay City$14.7M
- Neil FraserTroy$14.3M
- Abdulhassan SaadDearborn$11.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.